Drugs / peginterferon beta-1a
peginterferon beta-1a
also known as
BIIB017 · Peginterferon β-1a · PEG-IFN beta-1a · Peginterferon beta · PEGylated Interferon Beta-1a · pegylated interferon-β1a · Plegridy
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | PLEGRIDY | — | 2020-03-27 – 2021-01-29 | fda.gov ↗ |
| Approved | US (FDA) | PLEGRIDY | — | 2014-08-15 | fda.gov ↗ |
| Approved | EU (EMA) | Plegridy | — | 2014-07-18 | europa.eu ↗ |
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT04183491 | Feb 2020 → Jan 2021 | — | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Phase 1 | NCT02269930 | Oct → Dec 2014 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01978652 | Dec 2013 → Feb 2014 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT01119781 | May 2010 → Aug 2011 | impaired renal function disease | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT02125578 | Mar → May 2008 | — | Biogen | Completed | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT03958877 | Oct 2019 → May 2027 expected | relapsing-remitting multiple sclerosis | Biogen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03870763 | Mar 2019 → Jul 2022 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT05242133 | Dec 2017 → Apr 2022 | relapsing-remitting multiple sclerosis | Cinnagen | Completed | No outcome recorded |
| Phase 3 | NCT01939002 | Nov 2013 → Oct 2015 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT01332019 | Apr 2011 → Oct 2015 | multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT01337427 | Aug 2010 → Aug 2013 | relapsing-remitting multiple sclerosis | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 3 | NCT00906399 | Jun 2009 → Oct 2012 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02587065 | Feb 2016 → Oct 2017 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT02234869 | Oct 2014 → Feb 2017 | multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT04788615 Comparator | Jul 2021 → Nov 2025 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04552379 Comparator | Dec 2020 → May 2021 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT03424733 Background | Sep 2017 → May 2020 | multiple sclerosis | Holy Name Medical Center, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT03177083 Comparator | Jan 2017 → Oct 2020 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 4 | NCT02568111 Background | Feb → Aug 2016 | relapsing-remitting multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | peginterferon beta-1a | “Efficacy and safety of peginterferon beta-1a compared to interferon beta-1a in relapsing remitting multiple sclerosis patients” PMID 39217809 ↗ Aug 202414“Peg-Interferon beta-1a minimum dose of 63µg or maximum dose of 125µg every 2 weeks (14 days)” NCT04788615 ↗ “Drug: BIIB017 (peginterferon beta-1a)” NCT03958877 ↗ |
| Known as | BIIB017 | “BIIB017 (peginterferon beta-1a)” NCT00906399 ↗ |
| Known as | PEG-IFN beta-1a | “This study clinically evaluated a novel PEGylated form of interferon beta-1a (PEG-IFN beta-1a), a potential first-line treatment for relapsing multiple sclerosis, in healthy volunteers.” PMID 21680782 ↗ Jun 2011 |
| Known as | Peginterferon beta | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108677 ↗ |
| Known as | Peginterferon β-1a | “Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing-remitting...” PMID 30181780 ↗ Aug 20181“Single-use autoinjector for peginterferon-β1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study.” PMID 25073663 ↗ Jul 2014 |
| Known as | PEGylated Interferon Beta-1a | “BIIB017 (PEGylated Interferon Beta-1a)” NCT02125578 ↗ |
| Known as | pegylated interferon-β1a | “a pegylated interferon-β1a in clinical development” PMID 25073663 ↗ Jul 2014 |
| Known as | Plegridy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03424733 ↗ |
| Modality | Protein / enzyme biologic | “PEGylated Interferon Beta-1a (BIIB017)” NCT01119781 ↗ |
| Route | Subcutaneous | “self-administered by subcutaneous injection” NCT00906399 ↗ |